Korea's LG Life Sciences Signs Deal With China's Double-Crane Covering DPP-4 Inhibitor Gemigliptin
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's LG Life Sciences has signed an exclusive license, supply and distribution agreement with China's Double-Crane Pharmaceutical, under which the Chinese company will sell - inside China - LG's DPP-4 inhibitor Gemigliptin for treatment of diabetes
You may also be interested in...
Korea’s Dong-A Out-licenses DPP-4 To India’s Alkem Laboratories
Staggering under a tightened regulatory grip and price cuts at home, Korea’s Dong-A is trying to capture growth momentum from overseas.
Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?
After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.
Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?
After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.